Open AccessThe Immun System Response İn Covıd-19 Infectıon İn Polycystıc Ovary Syndrome
Author(s) -
Gülcan Arusoğlu,
Kübra Bozay
Publication year - 2021
Publication title -
international journal of medical science and clinical invention
Language(s) - English
Resource type - Journals
eISSN - 2454-9576
pISSN - 2348-991X
DOI - 10.18535/ijmsci/v8i05.05
Subject(s) - medicine , hyperandrogenism , polycystic ovary , disease , metabolic syndrome , diabetes mellitus , insulin resistance , covid-19 , pathophysiology , vitamin d and neurology , pandemic , obesity , intensive care medicine , endocrinology , infectious disease (medical specialty)
COVID-19, globally affecting people's lives, is a respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which reaches the pandemic state. People who are vulnerable and not immunocompromised are known to suffer severe COVID-19 complications and are at a relatively high risk of death. Risk factors include age, male gender, cardiovascular comorbidities including hypertension, history of cardiovascular disease, insulin resistance, diabetes, and obesity. Emerging data also linked the risk of severe COVID-19 to certain factors such as hyper inflammation, low vitamin D levels, and hyperandrogenism. Androgens play a key role in the pathophysiology of this infection. Therefore requires risk assessment of women with the polycystic ovarian syndrome (PCOS), the most common endocrinopathy in women of reproductive age with a prevalence of 8-13%, suffering from hyperandrogenism and characterized by most metabolic diseases. In this article, possible pathophysiological mechanisms related to the risk of COVID-19 in women with PCOS will be discussed. More scientific research is needed to understand which women are most at risk of becoming infected or developing complications, what causal mechanisms are possible to intervene, and what the long-term consequences will be.